Michael Wulfsohn

6.7k total citations · 3 hit papers
35 papers, 4.5k citations indexed

About

Michael Wulfsohn is a scholar working on Epidemiology, Infectious Diseases and Hepatology. According to data from OpenAlex, Michael Wulfsohn has authored 35 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Epidemiology, 17 papers in Infectious Diseases and 17 papers in Hepatology. Recurrent topics in Michael Wulfsohn's work include Hepatitis B Virus Studies (17 papers), Hepatitis C virus research (16 papers) and HIV/AIDS drug development and treatment (15 papers). Michael Wulfsohn is often cited by papers focused on Hepatitis B Virus Studies (17 papers), Hepatitis C virus research (16 papers) and HIV/AIDS drug development and treatment (15 papers). Michael Wulfsohn collaborates with scholars based in United States, France and Singapore. Michael Wulfsohn's co-authors include Anastasios A. Tsiatis, Carol Brosgart, John Fry, Shelly Xiong, Patrick Marcellin, Seng Gee Lim, Zachary Goodman, Victor DeGruttola, Ting‐Tsung Chang and Myron J. Tong and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Statistical Association and Annals of Internal Medicine.

In The Last Decade

Michael Wulfsohn

34 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B

2003 1.0k citations Patrick Marcellin, Ting‐Tsung Chang et al. New England Journal of Medicine profile →
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B

2003 749 citations Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. New England Journal of Medicine profile →
A Joint Model for Survival and Longitudinal Data Measured with Error

1997 648 citations Michael Wulfsohn, Anastasios A. Tsiatis Biometrics profile →

Peers

Countries citing papers authored by Michael Wulfsohn

Since Specialization

Citations

This map shows the geographic impact of Michael Wulfsohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Wulfsohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Wulfsohn more than expected).

Fields of papers citing papers by Michael Wulfsohn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Wulfsohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Wulfsohn. The network helps show where Michael Wulfsohn may publish in the future.

Co-authorship network of co-authors of Michael Wulfsohn

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Wulfsohn. A scholar is included among the top collaborators of Michael Wulfsohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Wulfsohn. Michael Wulfsohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults 2014 ·Journal of Antimicrobial Chemotherapy ·Martin Markowitz, Andrew Zolopa, K. Squires, Peter Ruane, Dion F. Coakley, Brian P. Kearney, Lijie Zhong, Michael Wulfsohn, Michael D. Miller, (unknown)	103
2	Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients 2005 ·Journal of Viral Hepatitis ·C. Westland, Hao Yang, William E. Delaney, Michael Wulfsohn, Nicole Lama, Craig S. Gibbs, Michael D. Miller, John Fry, Carol Brosgart, Eugene R. Schiff, S. Xiong	54
3	Patterns of Resistance Emerging in HIV-1 From Antiretroviral-Experienced Patients Undergoing Intensification Therapy With Tenofovir Disoproxil Fumarate 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Damian J. McColl, Nicolas Margot, Michael Wulfsohn, Dion F. Coakley, Andrew Cheng, Michael D. Miller	40
4	Genotypic and Phenotypic Predictors of the Magnitude of Response to Tenofovir Disoproxil Fumarate Treatment in Antiretroviral‐Experienced Patients 2004 ·The Journal of Infectious Diseases ·Michael D. Miller, Nicolas Margot, Biao Lu, Lijie Zhong, Shanshan Chen, Andrew Cheng, Michael Wulfsohn	146
5	Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B breakdown → 2003 ·New England Journal of Medicine ·Patrick Marcellin, Ting‐Tsung Chang, Seng Gee Lim, Myron J. Tong, William Sievert, Mitchell L. Shiffman, Lennox J. Jeffers, Zachary Goodman, Michael Wulfsohn, Shelly Xiong, John Fry, Carol Brosgart	1010
6	Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV) 2003 ·Journal of Hepatology ·S. Xiong, (unknown), C. Westland, William E. Delaney, Danni Colledge, Angeline Bartholomeusz, Vincent Thibault, Y. Benhamou, P. Angus, Michael Wulfsohn, Craig S. Gibbs, John Fry, Carol Brosgart, S. Locarnini	35
7	Predicting HBEAG loss by HBV DNA early kinetics and HBV genotype during treatment of HBEAG+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV) 2003 ·Journal of Hepatology ·Avidan U. Neumann, (unknown), (unknown), Manuel Tsiang, Michael Wulfsohn, Carol Brosgart, John Fry, C. Westland, S. Xiong, Craig S. Gibbs	3
8	Week 48 Resistance Surveillance in Two Phase 3 Clinical Studies of Adefovir Dipivoxil for Chronic Hepatitis B 2003 ·Hepatology ·Christopher Westland, Huiling Yang, William E. Delaney, Craig S. Gibbs, Michael D. Miller, Michael Wulfsohn, John Fry, Carol Brosgart, Shelly Xiong	120
9	Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B breakdown → 2003 ·New England Journal of Medicine ·Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos, E. Jenny Heathcote, Ting‐Tsung Chang, G. Kitis, Mario Rizzetto, Patrick Marcellin, Seng Gee Lim, Zachary Goodman, Michael Wulfsohn, Shelly Xiong, John Fry, Carol Brosgart	749
10	1156 48 weeks of adefovir dipivoxil (ADV) results in a consistent and significant improvement in liver histology and virological status regardless of baseline knodell fibrosis score in patients with HBEAG- chronic hepatitis B 2003 ·Hepatology ·Patrick Marcellin, Stephanos J. Hadziyannis, Nikos Tassopoulos, E. Jenny Heathcote, Ting‐Tsung Chang, G. Kitis, Mario Rizzetto, (unknown), (unknown), Michael Wulfsohn	2
11	Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B 2003 ·Journal of Hepatology ·S. Hadziyannis, N. Tassopoulos, Jenny Heathcote, Ting‐Tsung Chang, G. Kitis, (unknown), Patrick Marcellin, (unknown), (unknown), Michael Wulfsohn, Michael R. Wollman, John Fry, Carol Brosgart	14
12	48 weeks of adefovir dipivoxil (ADV) results in improvement in fibrosis and decreased progression of fibrosis in a double-blind, randomized, placebo-controlled study for the treatment of patients with HBeAg plus chronic hepatitis B. 2002 ·Hepatology ·(unknown), Patrick Marcellin, Ting‐Tsung Chang, Seng Gee Lim, Myron J. Tong, William Sievert, (unknown), L. Jeffers, Michael Wulfsohn, Richard Fallis, John Fry, (unknown)	3
13	Phase II Double‐Blind, Placebo‐Controlled Study of the Safety and Efficacy of Cidofovir Topical Gel for the Treatment of Patients with Human Papillomavirus Infection 2001 ·Clinical Infectious Diseases ·Robert Snoeck, M. Bossens, Dominique Parent, B. Delaere, H. Degreef, (unknown), Jean‐Christophe Noël, Michael Wulfsohn, James F. Rooney, Howard S. Jaffe, Erik De Clercq	90
14	A Joint Model for Survival and Longitudinal Data Measured with Error breakdown → 1997 ·Biometrics ·Michael Wulfsohn, Anastasios A. Tsiatis	648
15	Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with AIDS 1995 ·Journal of the American Statistical Association ·Anastasios A. Tsiatis, Victor DeGruttola, Michael Wulfsohn	378
16	Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093) 1994 ·AIDS ·Mark Z. Jacobson, Michael Wulfsohn, Judith Feinberg, Roger B. Davis, Maureen Power, Susan Owens, Dennis Causey, Margo Heath‐Chiozzi, Robert L. Murphy, Tony Cheung, Douglas T. Dieterich, Stephen A. Spector, George McKinley, David M. Parenti, Clyde S. Crumpacker	17
17	Prevention of Relapse of Histoplasmosis with Itraconazole in Patients with the Acquired Immunodeficiency Syndrome 1993 ·Annals of Internal Medicine ·Joseph Wheat, Richard Hafner, Michael Wulfsohn, (unknown), Kathleen Squires, William G. Powderly, Brian W. Wong, Michael G. Rinaldi, Michael S. Saag, Richard J. Hamill, Robert L. Murphy, Patricia Connolly‐Stringfield, (unknown), Susan Owens	151
18	G-Estimation of the Effect of Prophylaxis Therapy for Pneumocystis carinii Pneumonia on the Survival of AIDS Patients 1992 ·Epidemiology ·James M. Robins, (unknown), Grant A. Ritter, Michael Wulfsohn	226
19	A Multicenter Trial of Oral Zidovudine in Children with Advanced Human Immunodeficiency Virus Disease 1991 ·New England Journal of Medicine ·Ross E. McKinney, Mary Maha, Edward M. Connor, Judith Feinberg, Gwendolyn B. Scott, Michael Wulfsohn, Kenneth McIntosh, William Borkowsky, John F. Modlin, Peggy Sue Weintrub, Karen O’Donnell, Richard D. Gelber, (unknown), Sandra Nusinoff Lehrman, Catherine M. Wilfert	156
20	A Randomized Controlled Trial of a Reduced Daily Dose of Zidovudine in Patients with the Acquired Immunodeficiency Syndrome 1990 ·New England Journal of Medicine ·Margaret A. Fischl, Corette B. Parker, Carla Pettinelli, Michael Wulfsohn, Martin Hirsch, Ann C. Collier, Diana Antoniskis, Monto Ho, Douglas D. Richman, Edward J. Fuchs, Thomas C. Merigan, Richard C. Reichman, Jonathan Gold, Neal H. Steigbigel, Gifford Leoung, Suraiya Rasheed, Anastasios A. Tsiatis	249

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact